A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies

Clinical Infectious Diseases

Volumn 43, Issue 4, 2006, Pages 447-459

  Bow, E J ^a,b,k   Rotstein, C ^c   Noskin, G A ^j   Laverdiere M ^e   Schwarer, A P ^f   Segal, B H ⁱ   Seymour, J F ^h   Szer, J ^g   Sanche, S ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^f ALFRED HOSPITAL   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ UNIVERSITY AT BUFFALO   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k HEALTH SCIENCES CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; COTRIMOXAZOLE; CYTOTOXIC AGENT; GLYCOPEPTIDE; HEMOPOIETIC GROWTH FACTOR; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANADA; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMPIRICAL RESEARCH; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES; VOMITING;

EID: 33746632124     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505393     Document Type: Article

References (67)

1. Garcia-Rodriguez JA, Gobernado M, Gomis M, et al. Clinical guide for the evaluation and treatment of patients with neutropenia and fever (in Spanish). Rev Esp Quimioter 2001; 14:75-83.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
3. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2):S105-17.
4. Freifeld AG, Baden LR, Brown AE, et al. Fever and neutropenia. J Natl Compr Canc Netw 2004; 2:390-432.
5. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326:1111-20.
6. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2:231-42.
7. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991; 164:907-16.
8. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41:1704-8.
9. Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42:511-8.
10. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3:324-30.
11. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34:989-95.
12. Chuang YY, Hung IJ, Yang CP, Jaing TH, Lin TY, Huang YC. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002; 21:203-9.
13. Fleming DR, Ziegler C, Baize T, Mudd L, Goldsmith GH, Herzig RH. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients. Am J Clin Oncol 2003; 26:285-8.
14. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98:1039-47.
15. Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem - cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996; 37:975-86.
16. Sanz MA, Bermudez A, Rovira M, et al. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. Curr Med Res Opin 2005; 21:645-55.
17. Reich G, Cornely OA, Sandherr M, et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 2005; 130:265-70.
18. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13:281-7.
19. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Annals of Hematology 1998; 76:73-80.
20. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1996; 40:1108-15.
21. de la Camara R, Figuera A, Sureda A, et al. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study. Haematologica 1997; 82:668-75.
22. Duzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001; 43:105-9.
23. Feld R, De Pauw B, Berman S, Keating A, Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18:3690-8.
24. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen. J Antimicrob Chemother 1995; 36:185-200.
25. Lindblad R, Rodjer S, Adreasson B, et al. Empiric monotherapy for febrile neutropenia- a randomized study comparing meropenem with ceftazidime. Scandinavian Journal of Infectious Diseases 1998; 30:237-43.
26. Vandercam B, Gerain J, Humblet Y, et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000; 79:152-7.
27. Fleischhack G, Hartmann C, Simon A, et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47:841-53.
28. Malik I, Shaharyar. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia. J Pak Med Assoc 2002; 52:15-8.
29. Shah PM, Heller A, Fuhr HG, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996; 24:480-4.
30. Petrilli AS, Cypriano M, Dantas LS, et al. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma. Braz J Infect Dis 2003; 7:111-20.
31. Williams ME, Harman C, Scheld M, Hess CE, Donowitz GR. A controlled study of ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host. Am J Med 1985; 79:67-72.
32. Bauduer F, Cousin T, Boulat O, et al. A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia. Leuk Lymphoma 2001; 42:379-86.
33. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int J Hematol 2004; 79:74-8.
34. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33:1295-301.
35. Gorschluter M, Hahn C, Fixson A, et al. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 2003; 11:362-70.
36. Hess U, Bohme C, Rey K, Senn HJ. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6:402-9.
37. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37:382-9.
38. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10:316-22.
39. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148:2561-8.
40. Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996; 10:223-37.
41. Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25:551-73.
42. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-91.
43. Feld R. Multinational cooperation in trials and guidelines dealing with febrile neutropenia. Int J Antimicrob Agents 2000; 16:185-7.
44. Feld R, Paesmans M, Freifeld AG, et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002; 35:1463-8.
45. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161:397-401.
46. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57:176-89.
47. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39:445-52.
48. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 1996; 14:2511-20.
49. Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol 1999; 10:1355-9.
50. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 1999; 17:3676-81.
51. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18:3558-85.
52. Erjavec Z, Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45:843-9.
53. Wade JC, Glasmacher A. Vancomycin does not benefit persistently febrile neutropenic people with cancer. Cancer Treat Rev 2004; 30:119-26.
54. Borland CD, Farrar WE. Reversible neutropenia from vancomycin. JAMA 1979; 24:2392-3.
55. Sanche SE, Dust WN, Shevchuk YM. Vancomycin-induced neutropenia resolves after substitution with teicoplanin. Clin Infect Dis 2000; 31:824-5.
56. Schwartz MD. Vancomycin-induced neutropenia in a patient positive for an antineutrophil antibody. Pharmacotherapy 2002; 22:783-8.
57. Segarra-Newnham M, Tagoff SS. Probable vancomycin-induced neutropenia. Ann Pharmacother 2004; 38:1855-9.
58. Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother 2000; 12(Suppl 5):21-5.
59. Glasmacher A, von Lillienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IGH, Prentice A. An evidenced-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005; 11:17-23.
60. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55:436-44.
61. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994; 89:519-23.
62. Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12:1217-23.
63. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 54:168-72.
64. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-53.
65. Peralta FG, Sanchez MB, Roiz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin Infect Dis 2003; 37:1568-72.
66. Kumar A, Choudhuri G, Aggarwal R. Piperacillin induced bone marrow suppression: a case report. BMC Clin Pharmacol 2003; 3:2.
67. Viscoli C, EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients, studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002; 38(Suppl 4):S82-7.